Treatment of large-vessel vasculitis (LVV) remains challenging. Patients usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC dose or after GC withdrawal. In addition, GCs are fraught with numerous adverse events. The aim of this study was to assess the efficacy and safety of the anti-IL-6 receptor (IL-6R) antibody tocilizumab (TCZ) in patients with LVV.
Tocilizumab: a novel therapy for patients with large-vessel vasculitis / Salvarani, Carlo; Magnani, Luca; Catanoso, Mariagrazia; Pipitone, Nicolò; Versari, Annibale; Dardani, Lucia; Pulsatelli, Lia; Meliconi, Riccardo; Boiardi, Luigi. - In: RHEUMATOLOGY. - ISSN 1462-0332. - 51:1(2012), pp. 151-156. [10.1093/rheumatology/ker296]
Tocilizumab: a novel therapy for patients with large-vessel vasculitis
SALVARANI, CARLO;
2012
Abstract
Treatment of large-vessel vasculitis (LVV) remains challenging. Patients usually respond to glucocorticoid (GC) therapy, but often relapse on tapering of the GC dose or after GC withdrawal. In addition, GCs are fraught with numerous adverse events. The aim of this study was to assess the efficacy and safety of the anti-IL-6 receptor (IL-6R) antibody tocilizumab (TCZ) in patients with LVV.
Pubblicazioni consigliate
I metadati presenti in IRIS UNIMORE sono rilasciati con licenza Creative Commons CC0 1.0 Universal, mentre i file delle pubblicazioni sono rilasciati con licenza Attribuzione 4.0 Internazionale (CC BY 4.0), salvo diversa indicazione.
In caso di violazione di copyright, contattare Supporto Iris
